EZH2 and prostate carcinoma: H3K27me3 methyltransferase is upregulated in a number of cancers, including prostate cancer [29], lymphoma [30]and ovaries [31].Notably, activating point mutations in EZH2 have been linked to B-cell lymphomas, supporting the notion that Enhancer of Zeste Homolog 2 (EZH2) possesses oncogenic properties [32].